This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beutner, K. R.
Right arrow Articles by Wood, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beutner, K. R.
Right arrow Articles by Wood, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 07 1995, 1546-1553, Vol 39, No. 7
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

KR Beutner, DJ Friedman, C Forszpaniak, PL Andersen and MJ Wood
Department of Dermatology, University of California at San Francisco, Vallejo 94589, USA.

Acyclovir treatment of acute herpes zoster speeds rash healing and decreases pain and ocular complications. The limited oral bioavailability of acyclovir necessitates frequent dosing. Valaciclovir, the l-valyl ester of acyclovir, is rapidly and almost completely converted to acyclovir in vivo and gives three- to fivefold increases in acyclovir bioavailability. In a randomized, double-blind, multicenter study, the safety and efficacy of oral valaciclovir given at a dosage of 1,000 mg three times daily for 7 or 14 days and oral acyclovir given at a dosage of 800 mg five times daily for 7 days were compared in immunocompetent adults aged > or = 50 years with herpes zoster. Patients were evaluated for 6 months. The intent-to-treat analysis (1,141 patients) showed that valaciclovir for 7 or 14 days significantly accelerated the resolution of herpes zoster-associated pain (P = 0.001 and P = 0.03, respectively) compared with acyclovir; median pain durations were 38 and 44 days, respectively, versus 51 days for acyclovir. Treatment with valaciclovir also significantly reduced the duration of postherpetic neuralgia and decreased the proportion of patients with pain persisting for 6 months (19.3 versus 25.7%). However, there were no differences between treatments in pain intensity or quality-of-life measures. Cutaneous manifestations resolved at similar rates in all groups. Adverse events were similar in nature and prevalence among groups, and no clinically important changes occurred in hematology or clinical chemistry parameters.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:

  • McGuigan, C., Balzarini, J. (2009). FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J Antimicrob Chemother 64: 671-673 [Abstract] [Full Text]  
  • Whitley, R. J. (2009). A 70-Year-Old Woman With Shingles: Review of Herpes Zoster. JAMA 302: 73-80 [Abstract] [Full Text]  
  • Goldblum, D, Bachmann, C, Tappeiner, C, Garweg, J, Frueh, B E (2008). Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. Br J Ophthalmol 92: 1201-1205 [Abstract] [Full Text]  
  • Opstelten, W., Eekhof, J., Neven, A. K., Verheij, T. (2008). Treatment of herpes zoster. cfp 54: 373-377 [Abstract] [Full Text]  
  • Quinlivan, M. L., Ayres, K., Ran, H., McElwaine, S., Leedham-Green, M., Scott, F. T., Johnson, R. W., Breuer, J. (2007). Effect of Viral Load on the Outcome of Herpes Zoster. J. Clin. Microbiol. 45: 3909-3914 [Abstract] [Full Text]  
  • Keeley, P. W., Waterhouse, E. T., Noble, S. I.R. (2007). The evidence base of palliative medicine: is inpatient palliative medicine evidence-based?. Palliat Med 21: 623-627 [Abstract]  
  • Opstelten, W., van Essen, G. A, Moons, K. G., van Wijck, A. J., Schellevis, F. G, Kalkman, C. J, Verheij, T. J. (2005). Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Fam Pract 22: 523-528 [Abstract] [Full Text]  
  • Gilden, D. H., Cohrs, R. J., Mahalingam, R. (2005). VZV vasculopathy and postherpetic neuralgia: Progress and perspective on antiviral therapy. Neurology 64: 21-25 [Abstract] [Full Text]  
  • MacDougall, C., Guglielmo, B. J. (2004). Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53: 899-901 [Abstract] [Full Text]  
  • Jung, B. F., Johnson, R. W., Griffin, D. R.J., Dworkin, R. H. (2004). Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62: 1545-1551 [Abstract] [Full Text]  
  • Hatanaka, T., Haramura, M., Fei, Y.-J., Miyauchi, S., Bridges, C. C., Ganapathy, P. S., Smith, S. B., Ganapathy, V., Ganapathy, M. E. (2004). Transport of Amino Acid-Based Prodrugs by the Na+- and Cl--Coupled Amino Acid Transporter ATB0,+ and Expression of the Transporter in Tissues Amenable for Drug Delivery. J. Pharmacol. Exp. Ther. 308: 1138-1147 [Abstract] [Full Text]  
  • Birch, C J, Druce, J D, Catton, M C, MacGregor, L, Read, T (2003). Detection of varicella zoster virus in genital specimens using a multiplex polymerase chain reaction. Sex. Transm. Infect. 79: 298-300 [Abstract] [Full Text]  
  • Gnann, J. W. Jr., Whitley, R. J. (2002). Herpes Zoster. NEJM 347: 340-346 [Full Text]  
  • Good, P, Stafford, B (2001). Inpatient palliative medicine is evidence based. Palliat Med 15: 493-498 [Abstract]  
  • Cunningham, A. L, Dworkin, R. H (2000). The management of post-herpetic neuralgia. BMJ 321: 778-779 [Full Text]  
  • Helgason, S., Petursson, G., Gudmundsson, S., Sigurdsson, J. A (2000). Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 321: 794-794 [Abstract] [Full Text]  
  • Tyring, S. K., Beutner, K. R., Tucker, B. A., Anderson, W. C., Crooks, R. J. (2000). Antiviral Therapy for Herpes Zoster: Randomized, Controlled Clinical Trial of Valacyclovir and Famciclovir Therapy in Immunocompetent Patients 50 Years and Older. Arch Fam Med 9: 863-869 [Abstract] [Full Text]  
  • Dworkin, R. H., White, P. F., Ahmed, H. E., Craig, W. F. (1999). No alternative to antiviral drugs for acute herpes zoster.. Anesth. Analg. 89: 1585-1586 [Full Text]  
  • Hwang, S. M., Kang, Y. C., Lee, Y. B., Yoon, K. B., Ahn, S. K., Choi, E. H. (1999). The Effects of Epidural Blockade on the Acute Pain in Herpes Zoster. Arch Dermatol 135: 1359-1364 [Abstract] [Full Text]  
  • Cohen, J. I., Brunell, P. A., Straus, S. E., Krause, P. R. (1999). Recent Advances in Varicella-Zoster Virus Infection. ANN INTERN MED 130: 922-932 [Abstract] [Full Text]  
  • Balfour, H. H. (1999). Antiviral Drugs. NEJM 340: 1255-1268 [Full Text]  
  • (1998). Update on drugs for herpes zoster and genital herpes. DTB 36: 77-79 [Abstract] [Full Text]  
  • (1997). Management of Varicella-Zoster Virus Infections. Journal Watch Dermatology 1997: 20-20 [Full Text]  
  • Kost, R. G., Straus, S. E. (1997). Postherpetic Neuralgia: Predicting and Preventing Risk. Arch Intern Med 157: 1166-1167 [Abstract]  
  • Jackson, J. L., Gibbons, R., Meyer, G., Inouye, L. (1997). The Effect of Treating Herpes Zoster With Oral Acyclovir in Preventing Postherpetic Neuralgia: A Meta-analysis. Arch Intern Med 157: 909-912 [Abstract]  
  • Kost, R. G., Straus, S. E. (1996). Postherpetic Neuralgia -- Pathogenesis, Treatment, and Prevention. NEJM 335: 32-42 [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»